Your browser doesn't support javascript.
loading
Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life.
Bellato, Alessio; Perrott, Nadia J; Marzulli, Lucia; Parlatini, Valeria; Coghill, David; Cortese, Samuele.
Affiliation
  • Bellato A; University of Southampton, Southampton, United Kingdom; University of Nottingham Malaysia, Semenyih, Malaysia. Electronic address: a.bellato@soton.ac.uk.
  • Perrott NJ; University of Southampton, Southampton, United Kingdom.
  • Marzulli L; Università degli Studi di Bari "Aldo Moro", Bari, Italy.
  • Parlatini V; University of Southampton, Southampton, United Kingdom; King's College London, London, United Kingdom; Solent NHS Trust, Southampton, United Kingdom.
  • Coghill D; University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia.
  • Cortese S; University of Southampton, Southampton, United Kingdom; Università degli Studi di Bari "Aldo Moro", Bari, Italy; Solent NHS Trust, Southampton, United Kingdom; New York University Child Study Center, New York.
Article in En | MEDLINE | ID: mdl-38823477
ABSTRACT

OBJECTIVE:

We conducted a systematic review and meta-analysis to quantify the effect of attention-deficit/hyperactivity disorder (ADHD) medication on quality of life (QoL), and to understand whether this effect differs between stimulants and non-stimulants.

METHOD:

From the dataset of a published network meta-analysis (Cortese et al., 20181), updated on 27th February 2023 (https//med-adhd.org/), we identified randomized controlled trials (RCTs) of ADHD medications for individuals aged 6 years or more with a diagnosis of ADHD based on the DSM (from third to fifth editions) or the International Classification of Diseases (ICD; ninth or tenth revision), reporting data on QoL (measured with a validated scale). The risk of bias for each RCTs was assessed using the Cochrane Risk of Bias tool 2. Multi-level meta-analytic models were conducted with R 4.3.1.

RESULTS:

We included 17 RCTs (5,388 participants in total; 56% randomized to active medication) in the meta-analyses. We found that amphetamines (Hedge's g = 0.51, 95% CI = 0.08, 0.94), methylphenidate (0.38; 0.23, 0.54), and atomoxetine (0.30; 0.19, 0.40) were significantly more efficacious than placebo in improving QoL in people with ADHD, with moderate effect size. For atomoxetine, these effects were not moderated by the length of intervention, and did not differ between children/adolescents and adults.

CONCLUSION:

In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and non-stimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes. Future research should explore whether, and to what degree, combining pharmacological and non-pharmacological interventions is likely to further improve QoL in people with ADHD. STUDY PREREGISTRATION INFORMATION Effects of pharmacological treatment for ADHD on quality of life a systematic review and meta-analysis; https//osf.io/;qvgps.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Am Acad Child Adolesc Psychiatry / J. Am. Acad. Child Adolesc. Psychiatr / Journal of the american academy of child and adolescent psychiatry Journal subject: PEDIATRIA / PSIQUIATRIA Year: 2024 Document type: Article Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Am Acad Child Adolesc Psychiatry / J. Am. Acad. Child Adolesc. Psychiatr / Journal of the american academy of child and adolescent psychiatry Journal subject: PEDIATRIA / PSIQUIATRIA Year: 2024 Document type: Article Country of publication: Estados Unidos